- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004188
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma.
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: cyclophosphamide
- Drug: topotecan hydrochloride
- Procedure: peripheral blood stem cell transplantation
- Procedure: autologous bone marrow transplantation
- Drug: etoposide
- Drug: melphalan
- Drug: doxorubicin hydrochloride
- Drug: vincristine sulfate
- Drug: cisplatin
- Drug: carboplatin
- Procedure: bone marrow ablation with stem cell support
- Biological: filgrastim
- Drug: isotretinoin
- Procedure: conventional surgery
- Radiation: radiation therapy
Detailed Description
OBJECTIVES:
Primary
- Compare the event-free survival in patients with newly diagnosed high risk neuroblastoma or ganglioneuroblastoma treated with myeloablative consolidation chemotherapy and autologous purged versus unpurged peripheral blood stem cells (PBSC).
- Compare the time to engraftment and CD34 content and tumor content by reverse transcriptase polymerase chain reaction (RT-PCR) of purged versus unpurged PBSC in patients treated with these regimens.
- Determine event-free survival of patients treated with dose intensive induction chemotherapy comprising cyclophosphamide, doxorubicin, and vincristine alternating with cisplatin and etoposide.
- Determine the toxicity of this dose-intensive induction chemotherapy regimen in these patients.
- Evaluate tumor resectability at second look or delayed surgery, response (complete response and very good partial response) at completion of induction therapy, tumor content of peripheral blood and bone marrow, and the comparison of historical data from CCG-3891 induction therapy in these patients.
Secondary
- Compare the toxicity of this myeloablative consolidation regimen using purged vs unpurged PBSC in these patients.
- Determine if event-free survival is predictable by RT-PCR positivity of the stem cell, minimal residual disease in bone marrow and peripheral blood after transplantation by immunocytology, and extent of disease as measured by MIBG after transplantation in patients treated with these regimens.
- Evaluate the prognostic impact of tumor biology on event free survival in patients treated with these regimens.
- Determine the incidence of relapse in the primary site after radiotherapy and in irradiated versus unirradiated metastatic sites in these patients.
- Assess the toxicity and tolerability of maintenance therapy with topotecan and cyclophosphamide after intensive induction therapy in patients who decline or are unable to receive myeloablative therapy.
- Determine the health-related quality of life of patients treated with these regimens.
- Compare late effects of these regimens on the growth, endocrine, pulmonary, and cardiac function of these patients vs general population standards.
- Determine the incidence of second malignant neoplasms in patients treated with these regimens.
- Determine the variability of isotretinoin pharmacokinetics and relationship to pharmacogenomic parameters in these patients.
- Correlate the isotretinoin pharmacokinetics and pharmacogenomic parameters and/or genetic variations in isotretinoin metabolic enzymes with event-free survival or systemic toxicity in these patients.
OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms for peripheral blood stem cell (PBSC) collection.
All patients receive induction chemotherapy comprising cyclophosphamide IV over 6 hours on days 0 and 1, doxorubicin IV and vincristine IV continuously over 72 hours on days 0-2, and filgrastim (G-CSF) subcutaneously (SC) or IV beginning on day 3 and continuing until blood counts recover for courses 1, 2, 4, and 6. Treatment alternates with courses 3 and 5 comprising etoposide IV over 2 hours on days 0-2, cisplatin IV over 1 hour on days 0-3, and G-CSF SC or IV beginning on day 4 and continuing until blood counts recover. Induction chemotherapy repeats every 3 weeks or when blood counts recover in the absence of disease progression or unacceptable toxicity.
After course 2 or 3 of induction chemotherapy, patients undergo PBSC collection, either purged or unpurged, depending on randomization. Patients continue on daily G-CSF until cell collection is complete.
- Arm I: Patients undergo unpurged PBSC collection until the target cell count is reached.
- Arm II: Patients undergo purged PBSC collection until the target cell count is reached.
Patients with immunocytology positive PBSC undergo purged autologous bone marrow collection or repeat purged or unpurged PBSC collection depending on individual patient characteristics.
All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy.
After induction therapy, patients achieving complete response, very good partial response, or partial response receive consolidation therapy comprising melphalan IV on days -7 to -5 followed by carboplatin IV and etoposide IV continuously over days -7 to -4. Patients receive purged or unpurged PBSC infusion or purged autologous bone marrow transplantation on day 0 followed by G-CSF SC or IV beginning 4 hours after completion of transplantation and continuing until blood counts recover. Beginning on day 66, patients receive oral isotretinoin twice daily for 14 days. Isotretinoin therapy repeats every 4 weeks for 6 courses.
After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days.
Patients not undergoing transplantation or who are ineligible for consolidation therapy receive maintenance therapy comprising cyclophosphamide IV over 30 minutes followed by topotecan IV over 30 minutes on days 0-4. Patients receive G-CSF SC or IV beginning on day 5 and continuing until blood counts recover. Maintenance therapy repeats every 3 weeks for 3 courses. After completion of maintenance therapy, patients receive radiotherapy as outlined above. Patients then receive oral isotretinoin twice daily for 14 days. Isotretinoin therapy repeats every 4 weeks for 6 courses.
Quality of life is assessed at 1* and 5 years.
Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually thereafter or until disease progression.
NOTE: * Patients under 5 years of age at 1 year are not assessed until 5 years.
PROJECTED ACCRUAL: A total of 486 patients will be accrued for this study within 4 years.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2T 5C7
- Alberta Children's Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Children's & Women's Hospital of British Columbia
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Janeway Children's Health and Rehabilitation Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
London, Ontario, Canada, N6A 4G5
- Children's Hospital of Western Ontario
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- McGill Cancer Centre at McGill University
-
Ste-Foy, Quebec, Canada, G1V 4G2
- Centre Hospitalier Universitaire de Quebec
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre at Pasqua Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Comprehensive Cancer Center at University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, United States, 85016-7710
- Phoenix Children's Hospital
-
-
California
-
Downey, California, United States, 90242-2814
- Southern California Permanente Medical Group
-
Loma Linda, California, United States, 92354
- Loma Linda University Cancer Institute at Loma Linda University Medical Center
-
Long Beach, California, United States, 90801
- Jonathan Jaques Children's Cancer Center at Miller Children's Hospital
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
Los Angeles, California, United States, 90048-1865
- Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
-
Madera, California, United States, 93638-8762
- Children's Hospital Central California
-
Sacramento, California, United States, 95825
- Kaiser Permanente Medical Center - Oakland
-
San Diego, California, United States, 92123-4282
- Children's Hospital and Health Center - San Diego
-
San Francisco, California, United States, 94115
- UCSF Comprehensive Cancer Center
-
Stanford, California, United States, 94305
- Stanford Cancer Center at Stanford University Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80218-1088
- Children's Hospital Cancer Center
-
-
Connecticut
-
Farmington, Connecticut, United States, 06360-2875
- Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Children's National Medical Center
-
-
Florida
-
Fort Myers, Florida, United States, 33901
- Lee Cancer Care of Lee Memorial Health System
-
Ft. Lauderdale, Florida, United States, 33316
- Broward General Medical Center Cancer Center
-
Gainesville, Florida, United States, 32610-0232
- University of Florida Shands Cancer Center
-
Hollywood, Florida, United States, 33021
- Memorial Cancer Institute at Memorial Regional Hospital
-
St. Petersburg, Florida, United States, 33701
- All Children's Hospital
-
Tampa, Florida, United States, 33607
- St. Joseph's Cancer Institute at St. Joseph's Hospital
-
West Palm Beach, Florida, United States, 33407
- Kaplan Cancer Center at St. Mary's Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Children's Memorial Hospital - Chicago
-
Chicago, Illinois, United States, 60612-7243
- University of Illinois at Chicago Cancer Center
-
Springfield, Illinois, United States, 62794-9620
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5289
- Indiana University Cancer Center
-
Indianapolis, Indiana, United States, 46260
- St. Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines, Iowa, United States, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, United States, 52242-1083
- Holden Comprehensive Cancer Center at University of Iowa
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536-0084
- Markey Cancer Center at University of Kentucky Chandler Medical Center
-
Louisville, Kentucky, United States, 40232
- Kosair Children's Hospital
-
-
Maine
-
Bangor, Maine, United States, 04401
- CancerCare of Maine at Eastern Maine Medial Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
- Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0238
- C.S. Mott Children's Hospital at University of Michigan
-
Grand Rapids, Michigan, United States, 49503-2560
- Spectrum Health Cancer Care - Butterworth Campus
-
Grosse Pointe Woods, Michigan, United States, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Kalamazoo, Michigan, United States, 49007-5341
- CCOP - Kalamazoo
-
Lansing, Michigan, United States, 48910
- Breslin Cancer Center at Ingham Regional Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Fairview University Medical Center - University Campus
-
Minneapolis, Minnesota, United States, 55404
- Children's Hospital of Minnesota - Minneapolis
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Children's Mercy Hospital
-
St. Louis, Missouri, United States, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198-3330
- UNMC Eppley Cancer Center at the University of Nebraska Medical Center
-
Omaha, Nebraska, United States, 68114-4113
- Children's Hospital of Omaha
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109-2306
- Sunrise Hospital and Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756-0002
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Cancer Center at Hackensack University Medical Center
-
Livingston, New Jersey, United States, 07039
- St. Barnabas Medical Center
-
New Brunswick, New Jersey, United States, 08903
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
-
Newark, New Jersey, United States, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, United States, 07503
- St. Joseph's Hospital and Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131-5636
- University of New Mexico Cancer Research and Treatment Center
-
-
New York
-
New York, New York, United States, 10016
- NYU Cancer Institute at New York University Medical Center
-
Valhalla, New York, United States, 10595
- New York Medical College
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Mission Hospitals - Memorial Campus
-
Charlotte, North Carolina, United States, 28232-2861
- Blumenthal Cancer Center at Carolinas Medical Center
-
Charlotte, North Carolina, United States, 28233-3549
- Presbyterian Cancer Center at Presbyterian Hospital
-
Durham, North Carolina, United States, 27710
- Duke Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3039
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, United States, 44195-5217
- Cleveland Clinic Taussig Cancer Center
-
Columbus, Ohio, United States, 43205-2696
- Columbus Children's Hospital
-
Dayton, Ohio, United States, 45404-1815
- Children's Medical Center - Dayton
-
Toledo, Ohio, United States, 43606
- Toledo Hospital
-
Toledo, Ohio, United States, 43614
- Medical College of Ohio Cancer Institute
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Cancer Institute at Oregon Health and Science University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- Palmetto Health South Carolina Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57117-5039
- Sioux Valley Hospital and University of South Dakota Medical Center
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37916
- East Tennessee Children's Hospital
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Texas Tech University Health Sciences Center School of Medicine
-
Austin, Texas, United States, 78701
- Children's Hospital of Austin
-
Fort Worth, Texas, United States, 76104-9958
- Cook Children's Medical Center - Fort Worth
-
Lubbock, Texas, United States, 79410
- Covenant Children's Hospital
-
San Antonio, Texas, United States, 78284-7811
- University of Texas Health Science Center at San Antonio
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- Fletcher Allen Health Care - University Health Center Campus
-
-
Virginia
-
Richmond, Virginia, United States, 23298-0037
- Massey Cancer Center at Virginia Commonwealth University
-
Roanoke, Virginia, United States, 24029
- Carilion Cancer Center of Western Virginia
-
-
Washington
-
Spokane, Washington, United States, 99220-2555
- Providence Cancer Center at Sacred Heart Medical Center
-
-
West Virginia
-
Huntington, West Virginia, United States, 25701
- Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
-
Morgantown, West Virginia, United States, 26506
- Mary Babb Randolph Cancer Center at West Virginia University Hospitals
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Madison, Wisconsin, United States, 53792-6164
- University of Wisconsin Comprehensive Cancer Center
-
Marshfield, Wisconsin, United States, 54449
- Marshfield Clinic - Marshfield Center
-
Milwaukee, Wisconsin, United States, 53226
- Midwest Children's Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed newly diagnosed neuroblastoma OR ganglioneuroblastoma, and/or evidence of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites, meeting 1 of the following criteria:
- Age greater than 18 months with stage IV disease, regardless of biologic factors
Age 12-18 months with stage IV disease meeting one of the following criteria:
- Any unfavorable biologic feature (e.g., MYCN amplification, unfavorable pathology, and/or DNA index = 1)
- Any biologic feature that is indeterminate, unsatisfactory, or unknown
At least 1 year old with the following:
- Stage IIa/IIb with MYCN amplification (> 10) AND unfavorable pathology
- Stage III with MYCN amplification (> 10) OR unfavorable pathology
Stage I, II, or IVS with disease progression to stage IV without interval chemotherapy
- No more than 3 weeks since progression
- Must have been enrolled on protocol CCG-B973, COG-ANBL00B1, or POG-9047
Less than 1 year old with the following:
- Stage III, IV, or IVS disease with MYCN amplification (> 10)
- Registration on protocol COG-ANBL00B1 required within 14 days of diagnosis
PATIENT CHARACTERISTICS:
Age:
- See Disease Characteristics
- 30 and under at time of diagnosis
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count ≥ 1,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Inadequate hematopoiesis secondary to bone marrow involvement with > 10% tumor infiltration allowed
Hepatic:
- Bilirubin ≤ 1.5 mg/dL
- ALT ≤ 300 units/L
Renal:
- Creatinine ≤ 1.5 mg/dL
- Creatinine clearance or glomerular filtration rate ≥ 60 mL/min
Cardiovascular:
- ECG normal
- Ejection fraction ≥ 55% by echocardiogram or MUGA OR
- Fractional shortening ≥ 28% by echocardiogram
Other:
- Able to tolerate peripheral blood stem cell collection
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception for at least 1 month prior to, during, and for 1 month after study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- See Disease Characteristics
- No more than 1 prior course of chemotherapy on the Intergroup low/intermediate risk neuroblastoma study (P9641, A3961)
Endocrine therapy:
- Not specified
Radiotherapy:
- Prior localized emergency radiotherapy to sites of life-threatening or function-threatening disease allowed
Surgery:
- Not specified
Other
- No other prior systemic therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm I (unpurged PBSC collection)
Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4).
Pts undergo unpurged PBSC collection until the target cell count is reached.
Surgical resection of the tumor after crs 5 of induct.
CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. purged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant.
Day 66, isotretinoin 2x day/14 days.
Isotretinoin every 4 wks 6 crs.
After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days.
Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5).
Maint every 3 wks/3 crs.
Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
|
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
|
|
Experimental: Arm II (unpurged PBSC collection)
Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4).
Immunocytology + PBSC undergo purged autologous bone marrow collection or repeat purged or unpurged PBSC collection.
Surgical resection of the tumor after crs 5 of induct.
CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4.
Unpurged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant.
Day 66, isotretinoin 2x day/14 days.
Isotretinoin every 4 wks 6 crs.
After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days.
Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5).
Maint every 3 wks/3 crs.
Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
|
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Event-free survival rate
Time Frame: Time from study registration until the time of the first occurrence of either relapse, progression, secondary malignancy, or death, or until the time of last contact with the patient if none of these events occurs, assessed up to 6 years
|
Time from study registration until the time of the first occurrence of either relapse, progression, secondary malignancy, or death, or until the time of last contact with the patient if none of these events occurs, assessed up to 6 years
|
|
Rate of occurrence of toxic (non disease-related) deaths where a toxic death will be "counted" if it occurs prior to the initiation of the immunotherapy
Time Frame: Up to day 42
|
Up to day 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to engraftment
Time Frame: Up to 6 years
|
Engraftment is defined as three consecutive measurements of ANC > 500.
|
Up to 6 years
|
|
CD34 content
Time Frame: Up to 6 years
|
Up to 6 years
|
|
|
Tumor content as measured by reverse transcriptase polymerase chain reaction
Time Frame: Up to 6 years
|
Up to 6 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Susan G. Kreissman, MD, Duke Cancer Institute
Publications and helpful links
General Publications
- Dubois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, Martinez D, Pawel B, Yanik G, Naranjo A, London WB, Kreissman S, Baker D, Attiyeh E, Hogarty MD, Maris JM, Giacomini K, Matthay KK. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging. 2012;2012:250834. doi: 10.1155/2012/250834. Epub 2012 Sep 25.
- Cantos MF, Gerstle JT, Irwin MS, Pappo A, Farley S, Cheang T, Kim PC. Surgical challenges associated with intensive treatment protocols for high-risk neuroblastoma. J Pediatr Surg. 2006 May;41(5):960-5. doi: 10.1016/j.jpedsurg.2006.01.059.
- Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006 Jul 15;107(2):417-22. doi: 10.1002/cncr.22004.
- Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. J Clin Oncol. 2014 Feb 20;32(6):527-34. doi: 10.1200/JCO.2013.51.2038. Epub 2014 Jan 13.
- Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG, Yanik GA. Comparison of (1)(2)(3)I-metaiodobenzylguanidine (MIBG) and (1)(3)(1)I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 1;56(7):1041-5. doi: 10.1002/pbc.22991. Epub 2011 Feb 15.
- Yanik GA, Parisi MT, Naranjo A, et al.: MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study. [Abstract] J Clin Oncol 28 (Suppl 15): A-9516, 2010.
- Kreissman SG, Villablanca JG, Diller L, et al.: Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): a Children's Oncology Group (COG A3973) study. [Abstract] J Clin Oncol 25 (Suppl 18): A-9505, 527s, 2007.
- Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep;14(10):999-1008. doi: 10.1016/S1470-2045(13)70309-7. Epub 2013 Jul 25.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Neuroblastoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Adjuvants, Immunologic
- Antibiotics, Antineoplastic
- Topoisomerase I Inhibitors
- Cyclophosphamide
- Carboplatin
- Etoposide
- Cisplatin
- Lenograstim
- Melphalan
- Doxorubicin
- Liposomal doxorubicin
- Vincristine
- Topotecan
- Isotretinoin
- Mechlorethamine
Other Study ID Numbers
- A3973
- COG-A3973 (Other Identifier: Children's Oncology Group)
- CCG-A3973 (Other Identifier: Children's Cancer Group)
- POG-A3973 (Other Identifier: Pediatric Oncology Group)
- CCG-39703 (Other Identifier: Children's Cancer Group)
- FHCRC-1631.00
- CDR0000067429 (Other Identifier: Clinical Trials.gov)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.